For brand, patient services, and market access leaders, affordability support is no longer a niche add-on. Public data indicate that more than 9 million U.S. adults ages 18 to 64 did not take medications as prescribed in 2021 because of cost, while out-of-pocket spending on prescription drugs rose 4.8% to $63 billion that year. At the same time, Medicare’s current drug-cost guidance explicitly points patients toward multiple affordability pathways, including Extra Help, State Pharmaceutical Assistance Programs (PAPs), manufacturer PAPs, and the Medicare Prescription Payment Plan. That combination of persistent patient burden and a growing support ecosystem means affordability support in a patient support program (PSP) has to do more than process applications. It has to triage patients into the right pathway quickly, connect affordability work to reimbursement and dispensing workflows, and report whether assistance actually improves therapy starts and persistence.

Affordability is now an access issue

For commercial teams evaluating PSP vendors, the real question is not whether affordability matters. It is where affordability support belongs in the patient journey. The answer is early. When patients delay a fill, abandon a prescription, or ration therapy because of cost, the failure is no longer just financial. It becomes a therapy-start and persistence problem. Public reporting based on CDC data shows that more than 9 million adults ages 18 to 64 did not take medications as prescribed in 2021 because of cost, and national out-of-pocket spending on prescription drugs continued to rise.

Medicare’s current structure makes the same point in a different way. Drug affordability is presented as a set of coordinated options, not a single benefit. Beneficiaries may be directed to Medicaid, Extra Help, State Pharmaceutical Assistance Programs, manufacturer PAPs, or a payment-plan option that smooths monthly bills. In 2026, beneficiaries move to catastrophic coverage after covered Part D out-of-pocket spending reaches $2,100, and Extra Help can reduce premiums and deductibles to zero for qualifying patients while capping pharmacy cost sharing at low fixed amounts before that threshold. That is a useful model for commercial PSP design. Affordability belongs next to reimbursement, education, and pharmacy coordination because patients do not experience those steps separately.

What a modern affordability workflow should include

A modern affordability workflow should start with routing logic, not paperwork. The first job is to determine what kind of help is even permissible and relevant for the patient’s coverage type. Medicare’s own materials make clear that different tools solve different problems. Extra Help and SPAPs can reduce actual costs for eligible beneficiaries. Manufacturer PAPs may lower prescription costs for some Medicare patients depending on program rules. The Medicare Prescription Payment Plan, by contrast, can spread costs over the year but does not reduce total drug expense. A PSP that cannot distinguish true savings from cash-flow support will overstate its own value and leave gaps in the patient experience.

That is why affordability support should be designed as a triage-and-resolution function. In practice, that means screening for eligibility, collecting the right documentation once, routing patients to the most appropriate pathway, and keeping that status visible to reimbursement teams, specialty pharmacies, and nurse navigators. If those groups operate in separate systems, patients end up repeating information, providers lose visibility, and first-fill delays grow harder to explain. Public sources do not publish a single therapy-agnostic blueprint for this work, but Medicare’s affordability framework strongly suggests that fragmentation is the risk to avoid.

Commercial teams also need to remember that manufacturer assistance is only one part of the broader affordability ecosystem. HRSA’s 340B Drug Pricing Program exists so covered entities can stretch scarce federal resources and reach more eligible patients with reduced-price outpatient drugs. For PSP design, the lesson is simple. Some patients will move through manufacturer programs, some through public programs, and some through safety-net channels. A vendor that treats affordability as a single lane will miss the real-world complexity of access.

What commercial teams should ask PSP vendors to measure

The strongest vendor conversations usually start with measurement. If affordability support is being positioned as part of a patient support program, sponsors should ask how the vendor defines success before first dispense and after therapy start. Useful measures include time from referral to affordability determination, completed application rate, approval rate by pathway, time from affordability approval to first dispense, abandonment after approval, and persistence at fixed intervals such as 30, 60, or 90 days. Public, cross-brand benchmarks for PAP enrollment rates and end-to-end time-to-first-dose were unspecified in the official and academic sources reviewed for this article, which is exactly why denominator definitions matter so much in vendor evaluation. Unclear definitions make performance claims hard to compare.

Commercial leaders should also expect nuance in the evidence. A recent study of branded imatinib in Medicare-age patients found that Part D enrollment increased initial out-of-pocket costs by $232, while the associated adherence change was modest and not statistically significant. That does not mean affordability is unimportant. It means affordability effects vary by therapy, benefit design, and patient population. A serious PSP vendor should be able to show where affordability support changes initiation or persistence in the brand’s actual context, not rely on generic claims.

Finally, teams should separate true affordability improvement from payment smoothing. Medicare explicitly states that the Medicare Prescription Payment Plan can help patients manage monthly expenses but does not lower drug costs. The same discipline should apply in commercial programs. A vendor should be able to tell you when it created real savings, when it improved cash-flow timing, and when it simply documented an unresolved barrier. That level of transparency is what makes affordability support operationally useful, rather than just administratively busy.

In a modern PSP, affordability support is best understood as part of access design, not as a downstream rescue step. The most credible programs triage patients early, align affordability work with reimbursement and pharmacy operations, and measure whether the help actually changes therapy starts and persistence. If your team is reassessing PSP design, a practical next step is to compare your current workflow against the multiple affordability pathways that Medicare itself now highlights, and ask whether your vendor can coordinate that complexity without adding friction for patients. For additional context, Serva Health’s commercial patient support resources are a useful place to continue the discussion.